74134-79-5

Upstream product

• 146444-81-7 Benzoic acid (S)-2-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-2-(toluene-4-sulfonyloxy)-ethyl ester 
• 166249-17-8 methyl (2R,3S)-3,4-O-isopropylidene-2,3,4-trihydroxy-2-O-(p-toluenesulfonyl)butanoate 
• 128142-60-9 Benzoic acid (S)-2-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-2-(toluene-4-sulfonyloxy)-ethyl ester 
• 1774-47-6 trimethylsulfoxonium iodide 
• 15186-48-8 2,3-isopropylidene-glyceraldehyde 
• 593-71-5 Chloroiodomethane 
• 128142-57-4 5,6-O-isopropylidene-2,3-di-O-methyl-D-araboascobate 
• 146444-80-6 Benzoic acid (S)-2-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-2-hydroxy-ethyl ester 
• 114184-97-3 (S)-1-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)ethane-1,2-diol 
• 50271-42-6 5,6-O-isopropylidene-D-isoascorbic acid 
• 126946-54-1 ethyl (2R,3R)-3,4-O-isopropylidene-2-p-toluenesulfonyl-3,4-dihydroxybutanoate 
• 136136-24-8 ((4S,5R)-5-(hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl butanoate 
• 136136-22-6 ((4R,5S)-5-(hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl acetate 
• 84379-54-4 (R)-2-(benzyloxy)-2-[(R)-2,2-dimethyl-1,3-dioxolan-4-yl]ethanol 

Downstream Products

• 171036-62-7 (2R,3S)-1-O-Benzyl-3,4-O-isopropylidenebutane-1,2,3,4-tetrol 
• 410095-16-8 (R)-5-(tert-Butyl-diphenyl-silanyloxy)-1-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-pent-3-yn-1-ol 
• 926653-19-2 4-[1-(4-methoxy-benzyloxy)-pent-4-ynyl]-2,2-dimethyl-[1,3]dioxolane 
• 926653-20-5 4-[6-(3-benzyloxymethyl-oxiranyl)-1-(4-methoxy-benzyloxy)-hex-4-ynyl]-2,2-dimethyl-[1,3]dioxolane 
• 926653-18-1 1-benzyloxy-2-(tert-butyl-dimethyl-silanyloxy)-9-(2,2-dimethyl-[1,3]dioxolan-4-yl)-9-(4-methoxy-benzyloxy)-non-5-yn-3-ol 
• 926653-36-3 methanesulfonic acid 1-[2-benzyloxy-1-(tert-butyl-dimethyl-silanyloxy)-ethyl]-7-(2,2-dimethyl-[1,3]dioxolan-4-yl)-7-(4-methoxy-benzyloxy)-hept-3-ynyl ester 
• 1293966-41-2 C₁₉H₂₄ClNO₅ 
• 1293966-66-1 C₂₀H₂₆ClNO₅ 
• 1293966-80-9 C₅₉H₉₇ClO₁₃Si 
• 1293966-55-8 C₆₅H₁₁₁ClO₁₃Si₂ 
• 140867-27-2 (2R,3R)-1,2-O-methylethylidene-4-phenylbutane-1,2,3-triol 
• 619315-57-0 (1R,5S)-5-(tert-Butyl-diphenyl-silanyloxy)-1-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-heptadec-3-yn-1-ol 
• 128057-00-1 (3R,4R)-3-O-benzyl-4,5-O-isopropylidene-3,4,5-trihydroxypentanal 
• 128111-95-5 (2R,3R)-2-<2-O-benzyl-3,4-O-isopropylidene-2,3,4-trihydroxybut-1-yl>-1,3-dithiane 

Relevant academic research and scientific papers

SUBSTITUTED TRICYCLICS AND METHOD OF USE

The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj?gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide

The invention relates to a packaging comprising a multitude (A) of at least 2 administration units comprising polymorphic trihydrated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide; or (B) of at least 2 administration units comprising polymorphic solvated or desolvated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide.

N- (6- ( (2R,3S) -3,4-DIHYDROXYBUTAN-2-YLOXY) -2- (4 - FLUOROBENZYLTHIO) PYRIMIDIN- 4 - YL) -3- METHYLAZETIDINE- 1 - SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR

There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6--4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE

There is provided crystalline forms of N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]1-azetidinesulfon-amide anhydrate. Such compounds/forms may be useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

From L-ascorbic acid to protease inhibitors: Practical synthesis of key chiral epoxide intermediates for aspartyl proteases

Efficient synthetic routes were developed to prepare a sizable amount (4-15 grams) of the chiral epoxides 4-6 as versatile intermediates for the synthesis of aspartyl protease inhibitors of therapeutic interest such as HIV protease and β-secretase. Oxidative cleavage of the C(2)-C(3) double bond of L-ascorbic acid followed by functional group manipulation led to the preparation of the epoxide 10, which was opened with an azide to yield a common aziridine intermediate 12. Through opening of the aziridine ring of 12 with either a carbon or a sulfur nucleophile, chiral epoxide precursors 4-6 could be prepared for various HIV protease inhibitors. Except for the final low melting epoxides 5 and 6, all intermediates were obtained as crystalline solids, thus the synthetic pathway can be easily applied to a large-scale synthesis of the chiral epoxides.

Total synthesis of (+)-obtusenyne

The stereoselective total synthesis of (+)-obtusenyne is described. The oxonene skeleton possessing trans-orientated alkyl substituents at the α,α′-positions was stereoselectively constructed via cyclization of the corresponding hydroxy epoxide promoted b

A new efficient and practical synthesis of 2-deoxy-L-ribose

An efficient and practical route for large-scale synthesis of 2-deoxy-l-ribose starting from l-ascorbic acid was developed in eight steps without chromatographic purification for all intermediates. Additionally, (2S,3R)-3,4-epoxy-1,2-O-isopropylidenebutane-1,2-diol, a versatile intermediate in carbohydrate synthesis, was also prepared readily in excellent yield as a key intermediate.

An improved synthesis of the C15-C28 fragment of laulimalide

The C15-C28 fragment of the paclitaxel-like antimicrotubule agent laulimalide has been synthesized in 12 linear steps from known epoxide 5, with an overall yield of 16%. The methyldihydropyran ring of the side chain was efficiently prepared using ring-closing olefin metathesis chemistry. The 19,20-diol stereochemistry originates in starting material 7 and the side chain was appended using a Kocienski-modified Julia coupling.